0000000000075542

AUTHOR

Robert Bartlett

showing 3 related works from this author

Impact of thymus on the generation of immunocompetence and diversity of antigen-specific MHC-restricted cytotoxic T-lymphocyte precursors.

1981

Cytotoxicity ImmunologicbiologyT-LymphocytesImmunologyGenes MHC Class IIMice NudeProteinsCell CommunicationThymus GlandMajor histocompatibility complexModels BiologicalMajor Histocompatibility ComplexMiceAntigen specificRadiation ChimeraImmunologybiology.proteinImmune ToleranceImmunology and AllergyCytotoxic T cellAnimalsImmunocompetenceSpleenInterleukin-1Immunological reviews
researchProduct

Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis.

1994

Sarcoidosis is a systemic granulomatous disorder of unknown origin. In respect to clinical and immunological characteristics, it is indistinguishable from berylliosis. As an approach to develop a murine model reflecting some aspects of sarcoidosis, we attempted to induce berylliosis in mice by treating inbred F1 mice (C57B16 x DBA/2) with 3 mg beryllium sulfate (BeSO4) per kg body weight intraperitoneally. Either pure BeSO4 or BeSO4 in combination with incomplete Freund's adjuvant was administered. Alternatively, pure BeSO4 was injected 2 days after a single application of cyclophosphamide (150 mg/kg). The spleen index, the spontaneous and phorbolmyristate acetate (PMA)-induced radical oxyg…

Systemic diseasePathologymedicine.medical_specialtySarcoidosisBerylliosisT-LymphocytesImmunologyMuriBiologyLymphocyte ActivationBerylliosisMiceImmune systemAnimal modelMacrophages AlveolarmedicineImmunology and AllergyGranulomatous disorderMacrophageAnimalsHumansGeneral Medicinemedicine.diseaseMice Inbred C57BLMice Inbred DBAImmune SystemImmunologyMacrophages PeritonealFemaleSarcoidosisBerylliumReactive Oxygen SpeciesSpleenInternational archives of allergy and immunology
researchProduct

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

1993

AbstractThe active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor (EGF)-dependent proliferation is inhibited by A77 1726 at an effective dose of 30–40 μM. A77 1726 appears to directly inhibit the EGF receptor tyrosine-specific kinase activity both in intact cells and purified EGF receptors at the same effective dose. These data suggest that leflunomide inhibits cellular proliferation by the inhibition of tyrosine-specific kinase activities.

MaleToluidinesmedicine.medical_treatmentBiophysicsHydroxybutyratesBiochemistryKB CellsCell LineHuman foreskin fibroblast cellStructural BiologyEpidermal growth factorNitrilesGeneticsmedicineTumor Cells CulturedAnimalsHumansEpidermal growth factor receptorKinase activityPhosphorylationReceptorMolecular BiologyCells CulturedSkinAniline CompoundsbiologyCell growthKinaseEpidermal growth factor receptorGrowth factorAnti-Inflammatory Agents Non-SteroidalCell BiologyIsoxazolesFibroblastsTyrosine-specific kinaseCell biologyErbB ReceptorsBiochemistryCrotonatesbiology.proteinCarcinoma Squamous CellPlatelet-derived growth factor receptorLeflunomideFEBS letters
researchProduct